GGrantIndex
← Leaderboards

Irving C Allen

Univ Of North Carolina Chapel Hill

$4,589,595
Attributed
$4,589,595
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,589,595 · 6

By mechanism

R01$3,273,735 · 2
K01$709,052 · 1
R21$427,815 · 1
R03$161,000 · 1
F32$17,993 · 1

Top collaborators

No co-investigators on record.

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Physiological

Research focus

PhysiologicalTumorIn VivoMalignant NeoplasmsImmune ResponseResponseImmune SystemFuturePre-ClinicalMediatingStructurePathogenesisNovel Therapeutic InterventionMouse ModelFeedbackIn SituNoduleElectroporationLocationDiagnosisDuct (Organ) StructureCessation Of LifeClinical TranslationMalignant Neoplasm Of Pancreas

Grant awards (18)

Optimization of High Frequency Irreversible Electroporation (H-FIRE) for tumor ablation and immune system activation in pancreatic cancer applications$516,873
R01 · FY2025 · CA · contact PI
Deploying Histotripsy Based Tumor Ablation Strategies to Treat Pancreatic Cancer$375,828
R01 · FY2025 · CA · contact PI
Optimization of High Frequency Irreversible Electroporation (H-FIRE) for tumor ablation and immune system activation in pancreatic cancer applications$528,946
R01 · FY2024 · CA · contact PI
Deploying Histotripsy Based Tumor Ablation Strategies to Treat Pancreatic Cancer$360,593
R01 · FY2024 · CA · contact PI
Optimization of High Frequency Irreversible Electroporation (H-FIRE) for tumor ablation and immune system activation in pancreatic cancer applications$566,567
R01 · FY2023 · CA · contact PI
Deploying Histotripsy Based Tumor Ablation Strategies to Treat Pancreatic Cancer$457,121
R01 · FY2023 · CA · contact PI
Deploying Histotripsy Based Tumor Ablation Strategies to Treat Pancreatic Cancer$467,807
R01 · FY2022 · CA · contact PI
Employing Novel Porcine Models of Orthotopic Pancreatic Cancer to Evaluate Histotripsy Based Tumor Ablation Strategies$233,553
R21 · FY2020 · EB · contact PI
Employing Novel Porcine Models of Orthotopic Pancreatic Cancer to Evaluate Histotripsy Based Tumor Ablation Strategies$194,262
R21 · FY2019 · EB · contact PI
Evaluating NLR Modulation of Canonical and Non-Canonical NF-kB Signaling in IBD$80,500
R03 · FY2016 · DK · contact PI
NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis$149,894
K01 · FY2015 · DK · contact PI
Evaluating NLR Modulation of Canonical and Non-Canonical NF-kB Signaling in IBD$80,500
R03 · FY2015 · DK · contact PI
NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis$149,894
K01 · FY2014 · DK · contact PI
NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis$149,894
K01 · FY2013 · DK · contact PI
NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis$90,697
K01 · FY2012 · DK · contact PI
NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis$38,988
K01 · FY2012 · DK · contact PI
NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis$129,685
K01 · FY2011 · DK · contact PI
NLR regulation of innate immune responses to respiratory virus infection$17,993
F32 · FY2009 · AI · contact PI